Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.

Shah DR, Dholakia S, Shah RR.

Drug Saf. 2014 Mar;37(3):135-49. doi: 10.1007/s40264-014-0139-x. Review.

PMID:
24526268
2.

Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 Jul;36(7):491-503. doi: 10.1007/s40264-013-0048-4. Review.

PMID:
23620168
3.

Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.

Miller JA, Balagamwala EH, Angelov L, Suh JH, Rini B, Garcia JA, Ahluwalia M, Chao ST.

J Neurosurg Spine. 2016 Dec;25(6):766-774. Epub 2016 Jul 8.

PMID:
27391397
4.

Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Shah RR, Morganroth J, Shah DR.

Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5. Review.

PMID:
23620167
5.

Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Shah DR, Shah RR, Morganroth J.

Drug Saf. 2013 Jun;36(6):413-26. doi: 10.1007/s40264-013-0050-x. Review.

PMID:
23620170
6.

Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Irvine E, Williams C.

Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3. Review.

PMID:
23553655
7.

Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, Lefrandt JD, Links TP, Dekkers OM.

Eur J Endocrinol. 2015 May;172(5):R215-25. doi: 10.1530/EJE-14-0788. Epub 2015 Jan 8. Review.

8.

Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Miyake H, Imai S, Harada K, Fujisawa M.

Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15.

PMID:
26382221
9.

Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.

Wong SF, Mirshahidi H.

Ann Pharmacother. 2011 Jun;45(6):787-97. doi: 10.1345/aph.1P784. Epub 2011 Jun 13. Review.

PMID:
21672900
10.
11.

Mechanisms of TKI-induced diarrhea in cancer patients.

Bowen JM.

Curr Opin Support Palliat Care. 2013 Jun;7(2):162-7. doi: 10.1097/SPC.0b013e32835ec861. Review.

PMID:
23399616
12.

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.

JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.

PMID:
24715074
13.

Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Parikh P, Prabhash K, Naik R, Vaid AK, Goswami C, Rajappa S, Noronha V, Joshi A, Chacko RT, Aggarwal S, Doval DC.

Indian J Cancer. 2016 Jan-Mar;53(1):87-91. doi: 10.4103/0019-509X.180863. Review.

14.

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Ou SH, Soo RA.

Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Review.

15.

Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.

Teo YL, Ho HK, Chan A.

Cancer Treat Rev. 2013 Apr;39(2):199-206. doi: 10.1016/j.ctrv.2012.09.004. Epub 2012 Oct 23.

PMID:
23099278
16.
17.

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Breccia M, Colafigli G, Molica M, Alimena G.

Expert Opin Drug Saf. 2016;15(4):525-33. doi: 10.1517/14740338.2016.1145654. Epub 2016 Feb 16. Review.

PMID:
26799331
18.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.

Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J.

Leuk Lymphoma. 2014 Dec;55(12):2879-86. doi: 10.3109/10428194.2013.831092. Epub 2013 Sep 10.

19.

Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.

Kawano N, Yoshida S, Kawano S, Kuriyama T, Yamashita K, Ochiai H, Shimoda K, Ishikawa F, Ueda A, Kikuchi I.

J Clin Exp Hematop. 2016;56(1):34-42. doi: 10.3960/jslrt.56.34.

20.

Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.

Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS.

Oral Oncol. 2015 Nov;51(11):1026-1033. doi: 10.1016/j.oraloncology.2015.09.003. Epub 2015 Oct 5.

PMID:
26403941

Supplemental Content

Support Center